A substrate of choice to produce your vaccine

Valneva's EB66® duck cell line is a state-of-the-art vaccine production technology and one of the most extensively studied and characterized cell lines available today for the development and production of human and veterinary commercial vaccines.

Advantages

The EB66® cell line is one of the best alternatives to chicken eggs and other cell lines.

In an independent publication, EB66® was proven to bring significant cost savings due to its rapid population doubling time that can multiply twice as fast as Vero cells.

EB66® cells are able to grow in suspension in high-density which further shortens production campaigns and reduces vessel sizes. In addition, the upscalability of EB66® cell growth in stirred tank bioreactors has been demonstrated up to the 4,500 L scale.

EB66® is the only duck cell line to be fully documented in a biologics master file with the US Food and Drug Administration. EB66® is also well known by many equivalent authorities across Europe, Latin America, Asia and Africa.

  • Susceptible to a broad range of viruses
  • Indefinite self-renewal
  • Genetically stable
  • Scalable
  • Growth in suspension shortens production campaigns and reduce vessel sizes
  • Serum-free and chemically-defined medias available commercially
  • High yielding
  • Free of any contaminant organisms

 


 

Partnerships

The EB66® cell line is one of the most extensively studied and characterized cell lines available for use in human vaccines development

With 80+ commercial and research partnerships to date worldwide, EB66® has been tested in over 100 pathogens and a broad range of both human and veterinary viruses have successfully grown into it. Since its introduction in 2007, materials derived from the substrate have been administered in numerous human and animal clinical trials. In fact, there are currently 9 approved human and animal commercial vaccines based on EB66®.

 


 

Approved vaccines based on EB66® in the U.S., Europe, Japan and Latin America

Human vaccines

  • Pandemic H5N1 influenza
  • Pandemic influenza

Veterinary vaccines

  • Egg Drop Syndrome (2 different vaccines)
  • Muscovy Duck Parvovirus
  • Inclusion body hepatitis virus
  • Infectious bursal disease virus
  • Avian Influenza
  • Parvovirus

 


 

Partners who work with us

 


 

Publications

 


 

Book a meeting with us

Valneva has collaborated with big pharma and biotechs alike, several of today’s leading global veterinary healthcare companies, as well as universities and research institutions. With such diverse experience, we offer tailored deal structures to meet each client’s needs.

We are attending the World Vaccine Congress Europe, the World Vaccine Congress US and the BIO International Convention in the US every year, and would be happy to meet potential partners there.

We would be pleased to learn about your project in an initial discussion to see how EB66® can support you.

To reach us, please call +33 2 28 07 37 10 or complete the form below. We will get in touch shortly.


    * Indicated required field